Brenda is a senior healthcare consultant in the Health Practice of the Indianapolis office of Milliman. She is a lead in the pharmaceutical consulting group and is one of the developers of Milliman DNA. She joined the firm in 2008.
Brenda has been consulting to life sciences companies since 2008, in areas specific to market access and payer strategy. Her two primary focus areas are: (1) consulting related to gene and cell therapies and the rare diseases they treat, and (2) leading strategy projects that involve clinical and economic research.
Brenda is one of the developers of Milliman DNA gene and cell therapy forecasting, an interactive, web-based application that is used by health plans to analyze the emerging gene and cell therapy market to support underwriting, pricing and product development. She leads the clinical, market and economic research that form the baseline assumptions in this application and its associated research repository.
Brenda has more than 10 years of executive life sciences strategy experience gained at Eli Lilly and Company and Roche Diagnostics Corporation. During her tenure at those companies, she held global and U.S. leadership positions focused on pricing, value demonstration and payer marketing strategy.
Education
Publications
